Japanese researchers are testing a drug (TRG-035) that may allow people to regrow a third set of teeth by blocking the protein USAG-1, which naturally inhibits tooth growth. The drug has shown success in animal trials, and human clinical trials, which began in October 2024, are currently underway to evaluate its safety and effectiveness. If successful, the treatment could become available by 2030 as an alternative to implants and dentures.
How it works
- Inhibiting
a protein: The drug targets and blocks the USAG-1 protein.
- Removing
a growth blocker: USAG-1 normally acts as a "brake"
that prevents new teeth from growing.
- Activating
dormant buds: By blocking USAG-1, the drug effectively removes
this brake, allowing dormant "third-generation" tooth buds in
the jaw to activate and grow new, natural teeth.
Current status
- Human
trials: Human clinical trials began in October 2024 at Kyoto
University Hospital.
- Participants: The
first phase involves 30 adults who are missing at least one tooth, with
researchers monitoring them over an 11-month period.
- Future
plans: If successful, the next phases of trials will focus on
children with congenital tooth agenesis (missing teeth from birth).
- Timeline: The
researchers hope the treatment could be available to the public by 2030.
Comments
Post a Comment